Prime Medicine

PRMEPhase 2

Prime Medicine is built upon the groundbreaking Prime Editing technology, invented in the lab of Dr. David R. Liu and published in Nature in 2019. The company's mission is to deliver a new class of one-time curative genetic therapies by deploying its versatile and precise editing platform, which avoids double-strand DNA breaks. With a leadership team combining deep biotech experience and scientific founders at the forefront of gene editing, Prime Medicine is focused on translating its platform into transformative treatments for patients.

Market Cap

$635.5M

PRME · Stock Price

USD 3.5211.85 (-77.10%)

Historical price data

AI Company Overview

Technology Platform

Prime Editing, a next-generation 'search-and-replace' gene editing platform that precisely corrects disease-causing mutations at their native genomic location without requiring double-strand DNA breaks.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
PM359	Chronic Granulomatous Disease	Phase 1/2

Funding History

Total raised: $670.5M

IPO$180.5MUndisclosedOct 20, 2022

Series B$175MCormorant Asset ManagementOct 15, 2022

Series A$315MArch Venture PartnersSep 15, 2021

Opportunities

The primary growth opportunity lies in leveraging the Prime Editing platform to develop curative therapies for a vast array of genetic diseases, both rare and common.

Success could lead to a dominant position in next-generation gene editing, enabling both proprietary drug development and lucrative platform licensing or partnership deals with larger pharmaceutical companies.

Risk Factors

Key risks include the unproven clinical safety and efficacy of the novel Prime Editing technology, intense competition from other gene editing modalities, significant regulatory hurdles for gene therapies, and the high cash burn rate inherent in platform biotech companies with no near-term revenue.

Competitive Landscape

Prime Medicine competes with CRISPR-focused companies (CRISPR Therapeutics, Editas, Intellia), base editing specialists (Beam Therapeutics), and traditional gene therapy firms. Its differentiation is the precision and versatility of its Prime Editing platform, which aims to correct mutations without double-strand breaks, potentially offering a superior safety and efficacy profile.

Publications

Pipeline